Janssen Biotech, Aduro ink license deal worth $365M
BERKELEY, Calif.—An agreement was struck in late May between clinical-stage biotechnology company Aduro BioTech Inc. and Janssen Biotech Inc. that grants Janssen an exclusive, worldwide license to certain product candidates engineered for treating prostate cancer based on Aduro’s novel LADD immunotherapy platform. Per the agreement, Aduro stands to receive up to $365 million in upfront license fees and milestone payments if certain development, regulatory and commercialization milestones are met, should multiple programs be commercialized, in addition to tiered royalties on worldwide net sales. Janssen will be responsible for all research, development, manufacturing, regulatory and commercialization activities for the licensed products. In addition, under a separate agreement, Janssen has received exclusive rights to Aduro’s GVAX technology for prostate cancer.